Last $97.90 USD
Change Today +0.84 / 0.87%
Volume 228.0K
CVD On Other Exchanges
Symbol
Exchange
Stuttgart
As of 8:04 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

covance inc (CVD) Snapshot

Open
$97.97
Previous Close
$97.06
Day High
$98.00
Day Low
$96.74
52 Week High
04/3/14 - $106.50
52 Week Low
04/18/13 - $71.69
Market Cap
5.6B
Average Volume 10 Days
574.0K
EPS TTM
$3.25
Shares Outstanding
57.3M
EX-Date
--
P/E TM
30.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for COVANCE INC (CVD)

covance inc (CVD) Related Bloomberg News

View More Bloomberg News

covance inc (CVD) Related Businessweek News

No Related Businessweek News Found

covance inc (CVD) Details

Covance Inc. provides early-and late-stage services to the pharmaceutical, biotechnology, and medical device industries. Its early-stage development services include preclinical and clinical pharmacology services. The company’s late-stage services include biomarker services to biotech and pharmaceutical customers, with full management of Phase II and III clinical studies. It also provides lab testing services to the chemical, agrochemical, and food industries. The company was founded in 1987 and is based in Princeton, N.J.

11,863 Employees
Last Reported Date: 02/27/14
Founded in 1987

covance inc (CVD) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.0M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $407.5K
Executive Vice President and Group President ...
Total Annual Compensation: $455.5K
Executive Vice President and Group President ...
Total Annual Compensation: $421.0K
Chief Information Officer, Corporate Senior V...
Total Annual Compensation: $446.0K
Compensation as of Fiscal Year 2013.

covance inc (CVD) Key Developments

Covance Inc. Presents at Raymond James 35th Annual Institutional Investors Conference, Mar-03-2014 04:35 PM

Covance Inc. Presents at Raymond James 35th Annual Institutional Investors Conference, Mar-03-2014 04:35 PM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, Florida, United States.

Covance Board of Directors Adopts Amended and Restated By-Laws

On February 18, 2014, the Board of Directors adopted the Amended and Restated By-Laws of Covance Inc. The Amended and Restated By-Laws are substantially identical to the current By-Laws except that Section 1.09 of the By-Laws has been amended to require a stockholder proposing business to be brought before the annual meeting of stockholders to disclose information relating to derivative instruments relating to the Corporation and other rights with respect to securities of the Corporation held by such stockholder. In addition, a new Section 6.03 has been added providing that certain actions against the Corporation or its officers or directors, such as stockholder derivative actions, actions asserting breach of fiduciary duty or actions arising pursuant to the Corporation's By-Laws, Certificate of Incorporation or Delaware General Corporation Law, shall be exclusively brought in the state courts of Delaware (or if no state court in Delaware has jurisdiction, the Federal district court for the District of Delaware).

Covance Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2013; Provides Earnings Guidance for the First Quarter and Full Year 2014

Covance Inc. reported earnings results for the fourth quarter and year ended December 31, 2013. The company reported that net income for the fourth quarter ended December 31, 2013 was $45.85 million, or $0.80 per diluted share, compared to $33.90 million, or $0.61 per diluted share, for the same quarter ended December 31, 2012. Total revenues for the fourth quarter ended December 31, 2013 were $669.77 million, compared to $609.14 million for the same quarter ended December 31, 2012. Net income for the year ended December 31, 2013 was $179.21 million, or $3.15 per diluted share, compared to $94.73 million, or $1.68 per diluted share, for the year ended December 31, 2012. Total revenues for the year ended December 31, 2013 were $2.59 billion, compared to $2.36 billion for the year ended December 31, 2012. In the first quarter of 2014, the company expects revenue to be up from the fourth quarter level and pro forma earnings per share to increase sequentially by a couple of cents, as the company forecasted an increase in Late-Stage Development net revenues and earnings to be partially off-set by seasonally-lower first quarter Early Development results. Looking ahead to 2014, for the full year, the company expects year-on-year revenue growth in the 6% to 10% range and pro forma diluted earnings per share, excluding costs from ongoing restructuring activities, in the range of $3.65 to $4.00 (assuming foreign exchange rates remain at year-end 2013 levels).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CVD:US $97.90 USD +0.84

CVD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $57.62 USD +0.82
ICON PLC $43.90 USD +0.83
PAREXEL International Corp $49.96 USD +0.70
Quintiles Transnational Holdings Inc $50.60 USD -0.07
WuXi PharmaTech Cayman Inc $35.99 USD +0.85
View Industry Companies
 

Industry Analysis

CVD

Industry Average

Valuation CVD Industry Range
Price/Earnings 30.8x
Price/Sales 2.2x
Price/Book 3.5x
Price/Cash Flow 18.3x
TEV/Sales 1.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COVANCE INC, please visit www.covance.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.